CAMBRIDGE, Mass.--Millennium Pharmaceuticals here has named Kenneth Conway to the position of president of predictive medicine, where he will lead a new initiative to develop genomics-derived products and services to predict, diagnose and monitor disease and drug response. Conway was previously senior vice-president and general manager of immuno diagnostics for Chiron Diagnostics, and had held several other executive positions with that company.
Nick Galakatos, Millennium's vice-president of new businesses, commented, "His appointment is consistent with Millennium's commitment to leverage its technology and retained rights by creating a family of new businesses." Millennium employs large-scale genetics, genomics, high-throughput screening, and bioinformatics to assist in the discovery and development of therapeutic and diagnostic products.